YU66502A - 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza - Google Patents

5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza

Info

Publication number
YU66502A
YU66502A YU66502A YUP66502A YU66502A YU 66502 A YU66502 A YU 66502A YU 66502 A YU66502 A YU 66502A YU P66502 A YUP66502 A YU P66502A YU 66502 A YU66502 A YU 66502A
Authority
YU
Yugoslavia
Prior art keywords
so2nr4r5
compounds
hydrogen
alkylpyrido
pyrimidines
Prior art date
Application number
YU66502A
Other languages
English (en)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Peter Laurence Toogood
Scott Norman Vanderwel
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU66502A publication Critical patent/YU66502A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Otkrivena su jedinjenja formule (I) gde: R2 je vodonik, alkil ili cikloalkil; R3 je vodonik, nizi alkil, nizi alkoksi, halogen, trifluorometil, nizi alkinil, nizi alkenil, nitril, nitro, -COR4, -CO2 R4, - CONR4 R5, -CONR4OR5, SO2NR4R5, -SO2R4, -SO3R4, formule (II) ili -NR4R5; Y je N ili CR7; R9 je nizi alkil, haloalkil ili aril; X i Z su nezavisno vodonik, halogen, nizi alkil, nizi alkoksi, trifluorometil, hidroksi, nitril, nitro, -NR4R5, N(O)R4R5, -NR4R5R6W, -SR6, -C(O)R4, -CO2R4, -CONR4R5, -SO2NR4R5, SO2R4, -SO3R4, P(O)(OR6)(OR5), -T(CH2)mQR4, -C(O)T(CH2)mOR4 ili -NR4C(O)T(CH2)mQR5; m je 1 do 6. Ova jedinjenja su korisna u lecenju poremecaja celijske proliferacije, kao sto je kancer, ateroskleroza i restenoze. Ova jedinjenja su jaki inhibitori ciklin zavisnih kinaza (cdks) i kinaza u kojima posreduje faktor rasta.
YU66502A 2000-03-06 2001-01-29 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza YU66502A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06

Publications (1)

Publication Number Publication Date
YU66502A true YU66502A (sh) 2005-09-19

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
YU66502A YU66502A (sh) 2000-03-06 2001-01-29 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza

Country Status (36)

Country Link
EP (1) EP1268476A1 (sh)
JP (1) JP2003528101A (sh)
KR (1) KR20020075805A (sh)
CN (1) CN1422268A (sh)
AP (1) AP2002002643A0 (sh)
AR (1) AR034119A1 (sh)
AU (1) AU2001233028A1 (sh)
BG (1) BG107161A (sh)
BR (1) BR0109056A (sh)
CA (1) CA2401368A1 (sh)
CO (1) CO5280200A1 (sh)
CR (1) CR6736A (sh)
CZ (1) CZ20022929A3 (sh)
DZ (1) DZ3308A1 (sh)
EA (1) EA200200802A1 (sh)
EE (1) EE200200506A (sh)
GT (1) GT200100037A (sh)
HN (1) HN2001000040A (sh)
HR (1) HRP20020798A2 (sh)
HU (1) HUP0300136A2 (sh)
IL (1) IL151480A0 (sh)
IS (1) IS6524A (sh)
MA (1) MA26881A1 (sh)
MX (1) MXPA02008535A (sh)
NO (1) NO20024235L (sh)
NZ (1) NZ520962A (sh)
OA (1) OA12227A (sh)
PA (1) PA8513201A1 (sh)
PE (1) PE20011177A1 (sh)
PL (1) PL358271A1 (sh)
SK (1) SK12472002A3 (sh)
SV (1) SV2001000338A (sh)
TN (1) TNSN01036A1 (sh)
WO (1) WO2001070741A1 (sh)
YU (1) YU66502A (sh)
ZA (1) ZA200207110B (sh)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MXPA03003612A (es) 2000-10-23 2003-06-19 Smithkline Beecham Corp Compuestos novedosos.
KR100639772B1 (ko) * 2001-02-12 2006-10-30 에프. 호프만-라 로슈 아게 6-치환된 피리도-피리미딘
WO2002068419A1 (fr) 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
US20030105115A1 (en) * 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
CN1646131A (zh) 2002-04-19 2005-07-27 史密丝克莱恩比彻姆公司 新化合物
WO2004011456A1 (en) 2002-07-31 2004-02-05 Danter Wayne R Protein tyrosine kinase inhibitors
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
BRPI0406809A (pt) * 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
EP1663204B1 (en) * 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
DK1685131T3 (da) 2003-11-13 2007-07-09 Hoffmann La Roche Hydroxyalkylsubstituerede pyrido-7-pyrimidin-7-oner
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1856053A1 (en) 2005-01-14 2007-11-21 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
EP1868612A4 (en) 2005-03-25 2010-03-24 Glaxo Group Ltd NOVEL CONNECTIONS
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
WO2006104917A2 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
EP1931670B1 (en) 2005-10-07 2012-09-12 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k
EP2322523B1 (en) * 2005-10-07 2019-01-02 Exelixis, Inc. Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PL2074122T3 (pl) 2006-09-15 2011-10-31 Pfizer Prod Inc Związki pirydo(2,3-D)pirymidynonowe i ich zastosowanie jako inhibitory PI3
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
BRPI0715566A2 (pt) * 2006-10-16 2013-07-02 Gpc Biotech Inc composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
US8138181B2 (en) * 2007-04-03 2012-03-20 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
RU2010101052A (ru) * 2007-06-15 2011-07-20 Банью Фармасьютикал Ко., Лтд (Jp) Производные бициклоанилина
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
EP2231656A1 (en) 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
CA2719538C (en) 2008-04-07 2014-03-18 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2010006438A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
UY32153A (es) 2008-09-30 2011-04-29 Exelixis Inc Inhibidores de piridomidinona de pi13ka(alfa) y mtor
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP2486037A4 (en) * 2009-10-09 2013-01-16 Afraxis Inc 8-ETHYL-6- (ARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
US8889696B2 (en) 2009-12-18 2014-11-18 Temple University—Of the Commonwealth System of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
UY33221A (es) 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
KR101434841B1 (ko) * 2010-08-05 2014-08-29 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 2-치환-8-알킬-7-옥소-7,8-디하이드로피리도[2,3-ｄ] 피리미딘-6-카르보니트릴 및 이의 용도
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
EP2646448B1 (en) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
PT2710005T (pt) * 2011-05-17 2016-11-16 Principia Biopharma Inc Inibidores de tirosina-quinase
CN104271576A (zh) * 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
MX363715B (es) * 2013-02-21 2019-03-29 Pfizer Formas solidas de un inhbidor de cdk4/6 selectivo.
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
WO2016015597A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
MA45920B1 (fr) 2016-08-15 2021-08-31 Pfizer Inhibiteurs de pyridopyrimidinone cdk2/4/6
KR102583737B1 (ko) * 2017-03-03 2023-09-26 오클랜드 유니서비시즈 리미티드 Fgfr 키나제 저해제 및 약학적 용도
BR112020015431A2 (pt) 2018-02-15 2020-12-08 Nuvation Bio Inc. Compostos heterocíclicos como inibidores de quinase
TW202035406A (zh) * 2018-12-07 2020-10-01 大陸商杭州英創醫藥科技有限公司 作為cdk-hdac雙通路抑制劑的雜環化合物
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
KR20230148235A (ko) * 2021-03-08 2023-10-24 지난 유니버시티 피리도피리미딘계 화합물 및 이의 응용
WO2024056091A1 (zh) * 2022-09-16 2024-03-21 华东师范大学 作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用
WO2024099403A1 (zh) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种具有软药性质的硫醚类化合物、药物组合物及其用途
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
EP0964864B1 (en) * 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
ES2310039T3 (es) * 1998-05-26 2008-12-16 Warner-Lambert Company Llc Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.

Also Published As

Publication number Publication date
SK12472002A3 (sk) 2003-04-01
HN2001000040A (es) 2001-09-06
PL358271A1 (en) 2004-08-09
CA2401368A1 (en) 2001-09-27
WO2001070741A1 (en) 2001-09-27
EA200200802A1 (ru) 2003-02-27
OA12227A (en) 2004-03-18
IL151480A0 (en) 2003-04-10
HUP0300136A2 (en) 2003-05-28
HRP20020798A2 (en) 2004-02-29
TNSN01036A1 (en) 2005-11-10
AR034119A1 (es) 2004-02-04
BG107161A (en) 2003-06-30
CR6736A (es) 2004-03-10
NZ520962A (en) 2003-09-26
PE20011177A1 (es) 2001-11-23
KR20020075805A (ko) 2002-10-05
NO20024235D0 (no) 2002-09-05
MA26881A1 (fr) 2004-12-20
CO5280200A1 (es) 2003-05-30
ZA200207110B (en) 2003-12-04
JP2003528101A (ja) 2003-09-24
MXPA02008535A (es) 2002-12-13
CN1422268A (zh) 2003-06-04
IS6524A (is) 2002-08-23
CZ20022929A3 (cs) 2003-02-12
GT200100037A (es) 2002-03-04
EE200200506A (et) 2004-02-16
SV2001000338A (es) 2001-11-30
AP2002002643A0 (en) 2002-12-31
NO20024235L (no) 2002-11-05
AU2001233028A1 (en) 2001-10-03
PA8513201A1 (es) 2003-06-30
DZ3308A1 (fr) 2001-09-27
BR0109056A (pt) 2003-06-03
EP1268476A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
YU66502A (sh) 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza
YU73300A (sh) Biciklični pirimidini i biciklični 3,4-dihidropirimidini kao inhibitori ćelijske proliferacije
KR101917972B1 (ko) ERK 억제제로서 티에노[2,3-c]피롤-4-온 유도체
TR200102001T2 (tr) P38 kinaz inhibitörleri olarak sübstitüe edilmiş pirazoller
YU50402A (sh) Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze
GEP20063915B (en) PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
DK0783505T3 (da) Pyrrolo[2,3-d]pyrimidiner og deres anvendelse
PE20020305A1 (es) 2-(4-PIRIDIL) AMINO-6-DIALCOXIFENIL-PIRIDO [2,3-d] PIRIMIDIN-7-ONAS COMO INHIBIDORES DE LA TIROSINA QUINASA
NO20000702L (no) cGMP PDE-inhibitorer for behandling av erektil dysfunksjon
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
UY27198A1 (es) Nuevos compuestos antiinflamatorios de bencimidazol
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
PE20020976A1 (es) Pirido-pirimidinas 6-sustituidas como inhibidores de quinasas
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
BR9909808A (pt) Pirazolopirimidinonas inibidoras de cgmp pde5 para o tratamento da disfunção sexual
AR053662A1 (es) Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
TNSN05188A1 (en) 4-aminopyrimidine-5-one
PE20020524A1 (es) 7-oxo-piridopirimidinas como inhibidores de quinasas
ATE353651T1 (de) 3-furylanaloga von toxoflavin als kinaseinhibitoren
PT1303512E (pt) Processo para a preparacao de arilacetilaminotiazoles
UA87895C2 (en) Substituted 5-phenyl pyrimidines i in therapy
DK157781A (da) Thiazolderivater fremgangsmaade til deres fremstilling samt deres anvendelse
MX2023012427A (es) Proceso mejorado para la preparacion de derivados de 7-(morfolinil)-2-(n-piperazinil) metiltieno [2,3-c] piridina.
TH50354A3 (th) 4 - อัลคีนิล (และอัลไคนิล) ออกซินโดล